Philadelphia, Pennsylvania


Email Jamie Sheller
Jamie Sheller
Jamie Sheller
Attorney • (800) 883-2299

Bypass Patients Face Increased Mortality Risk With Trasylol

Comments Off

There is an increased risk of mortality for bypass patients who have been treated with Trasylol (aprotinin). The results of a study indicating this link was recently published in the Journal of the American Medical Association. According to researchers, Trasylol was “associated with a 48% increase in risk of dying within five years of coronary artery bypass surgery. . . .” Trasylol is used to limit operative blood loss. An analysis of the study data showed that there is both perioperative and long-term risk with Trasylol in bypass patients. “Therefore, continued use of aprotinin in this population does not appear prudent, given that safer alternatives-aminiocaproic acid and tranexamic acid are available.” Other doctors agree with the researchers’ conclusions, but note the limits of the study design.